The impact of clinical and genetic screenings on the management of the multiple endocrine neoplasia type 1

scientific article published on 01 August 2007

The impact of clinical and genetic screenings on the management of the multiple endocrine neoplasia type 1 is …
instance of (P31):
scholarly articleQ13442814

External links are
P698PubMed publication ID17823710

P2093author name stringSheila Aparecida Coelho Siqueira
Marcel Cerqueira Cesar Machado
Delmar Muniz Lourenço
Marcelo Augusto Cortina Gonçalves dos Santos
Fabio Luiz de Menezes Montenegro
Rodrigo Almeida Toledo
Sergio Pereira Almeida Toledo
Flavia Lima Coutinho
Leontina Conceição Margarido
P433issue4
P921main subjectmultiple endocrine neoplasiaQ1553018
multiple endocrine neoplasia type 1Q3347154
P304page(s)465-476
P577publication date2007-08-01
P1433published inClinicsQ26841864
P1476titleThe impact of clinical and genetic screenings on the management of the multiple endocrine neoplasia type 1
P478volume62

Reverse relations

cites work (P2860)
Q37023603A differential diagnosis of inherited endocrine tumors and their tumor counterparts
Q35897668Biochemical, bone and renal patterns in hyperparathyroidism associated with multiple endocrine neoplasia type 1.
Q37808142Care for patients with multiple endocrine neoplasia type 1: the current evidence base
Q37056120Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors
Q64120689Could the Less-Than Subtotal Parathyroidectomy Be an Option for Treating Young Patients With Multiple Endocrine Neoplasia Type 1-Related Hyperparathyroidism?
Q94464331Editorial: Early Genetic and Clinical Diagnosis in MEN1
Q39129029Genetics of multiple endocrine neoplasia type 1 syndrome: what's new and what's old.
Q90290355Giant Prolactinoma Causing Hydrocephalus and Intracranial Hypertension as First Manifestations of Multiple Endocrine Neoplasia Type 1
Q35813450Growth hormone response to growth hormone-releasing peptide-2 in growth hormone-deficient little mice
Q37629658Guidelines for the management of neuroendocrine tumours by the Brazilian gastrointestinal tumour group
Q37261277Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma
Q51336795Is Routine Screening of Young Asymptomatic MEN1 Patients Necessary?
Q33822855Isolated familial somatotropinoma: 11q13-loh and gene/protein expression analysis suggests a possible involvement of aip also in non-pituitary tumorigenesis
Q36192096MEN1 redefined, a clinical comparison of mutation-positive and mutation-negative patients
Q35895509Narrowing the gap of personalized medicine in emerging countries: the case of multiple endocrine neoplasias in Brazil
Q35895460Pituitary tumors in patients with MEN1 syndrome.
Q35895464Post-surgical follow-up of primary hyperparathyroidism associated with multiple endocrine neoplasia type 1.
Q49154597Reoperative Surgery in Patients with Multiple Endocrine Neoplasia Type 1 Associated Primary Hyperparathyroidism.
Q33458398Sporadic medullary thyroid carcinoma: clinical data from a university hospital
Q35895469Surgical approach to medullary thyroid carcinoma associated with multiple endocrine neoplasia type 2.
Q27026980Surgical treatment of pancreatic endocrine tumors in multiple endocrine neoplasia type 1
Q58750857The Importance of an Early and Accurate MEN1 Diagnosis
Q35895519Total parathyroidectomy in a large cohort of cases with hyperparathyroidism associated with multiple endocrine neoplasia type 1: experience from a single academic center
Q38852179Utility of chromogranin A, pancreatic polypeptide, glucagon and gastrin in the diagnosis and follow-up of pancreatic neuroendocrine tumours in multiple endocrine neoplasia type 1 patients

Search more.